These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25936885)

  • 1. [Immunohistochemical detections of EGFR status in NSCLC].
    Wang J; Liu C; Zhong D; Xu D; Ning C; Ma Q
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):212-8. PubMed ID: 25936885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer.
    Hitij NT; Kern I; Sadikov A; Knez L; Stanič K; Zwitter M; Cufer T
    Clin Lung Cancer; 2017 May; 18(3):e187-e196. PubMed ID: 28089159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
    Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
    Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data.
    Gaber R; Watermann I; Kugler C; Vollmer E; Perner S; Reck M; Goldmann T
    Rom J Morphol Embryol; 2017; 58(4):1175-1184. PubMed ID: 29556606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
    Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
    Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
    Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
    J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of epidermal growth factor receptor gene mutations in advanced non-small cell lung cancer].
    Wang S; Han XH; Li JL; Hu XS; Wang XY; Gui L; Zhao LD; Sun Y; Shi YK
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):530-3. PubMed ID: 23157744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantum dots immunofluorescence histochemical detection of EGFR gene mutations in the non-small cell lung cancers using mutation-specific antibodies.
    Qu YG; Zhang Q; Pan Q; Zhao XD; Huang YH; Chen FC; Chen HL
    Int J Nanomedicine; 2014; 9():5771-8. PubMed ID: 25525358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
    Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
    J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
    Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
    Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
    Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
    Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.